<DOC>
	<DOCNO>NCT00320060</DOCNO>
	<brief_summary>The primary objective study evaluate safety tolerability Pyridorin ( pyridoxamine dihydrochloride ) 50 mg give orally twice daily patient diabetic kidney disease .</brief_summary>
	<brief_title>Effect Pyridorin Patients With Diabetic Nephropathy</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Pyridoxamine</mesh_term>
	<criteria>Males Females ( nonpregnant nonlactating ) 18 70 year age type 1 type 2 diabetes Sitting blood pressure &lt; =170/100 mm Hg week 2 1 Hemoglobin A1C &lt; =12 % week 2 Patients diagnosis diabetic nephropathy define 1 . Serum Creatinine &lt; =2.0 mg/dL week 2 1 2 . Urinary albumin excretion &gt; =300 mg/24 hour week 2 3 . Diagnosis diabetic retinopathy Creatinine clearance &gt; =40 mL/min week 2 1 Voluntary write consent participate study History allergic adverse response B vitamin History major cardiovascular cerebrovascular event History cancer except adequately treat basal squamous cell carcinoma skin History diabetic ketoacidosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2006</verification_date>
	<keyword>Diabetic nephropathy</keyword>
	<keyword>Advanced Glycation Endproduct Inhibitor</keyword>
	<keyword>Pyridorin</keyword>
	<keyword>Pyridoxamine</keyword>
</DOC>